Clinical Trial

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Name: (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma — clinical trial record (NCT05907954)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma

Protocol Amendment History 23 amendments

This ClinicalTrials.gov record has been amended 23 times since 2023-06-14; most recent amendment 2026-03-12.

Status change: Recruiting → Active, Not Recruiting 2026-03-12

Trial Details

NCT Number	NCT05907954
Lead Sponsor	IDEAYA Biosciences
Conditions	Uveal Melanoma
Enrollment	160 participants
Start Date	2023-07-03
Primary Completion	2027-04-30 (estimated)
Study Completion	2030-04-30 (estimated)
Updated on ClinicalTrials.gov	2026-03-16